Prasugrel: Difference between revisions

Revision as of 15:22, 6 February 2014

Prasugrel
EFFIENT^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Prasugrel
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

For patient information about Prasugrel, click here

Synonyms / Brand Names: EFFIENT^®

Overview

Prasugrel is a novel platelet inhibitor developed by Daiichi Sankyo Co. and produced by Ube and currently under clinical development in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). Prasugrel is a member of the thienopyridine class of ADP receptor inhibitors, like ticlopidine and clopidogrel (trade name Plavix). These agents are believed to reduce the aggregation ("clumping") of platelets by irreversibly binding to P2Y₁₂ receptors.

FDA Package Insert

Mechanism of Action

References

Template:WikiDoc Sources

@@ Line 18: / Line 18: @@
 ==FDA Package Insert==
-'''| [[XXXXX indications and usage|Indications and Usage]]'''
+'''| [[Prasugrel indications and usage|Indications and Usage]]'''
-'''| [[XXXXX dosage and administration|Dosage and Administration]]'''
+'''| [[Prasugrel dosage and administration|Dosage and Administration]]'''
-'''| [[XXXXX dosage forms and strengths|Dosage Forms and Strengths]]'''
+'''| [[Prasugrel dosage forms and strengths|Dosage Forms and Strengths]]'''
-'''| [[XXXXX contraindications|Contraindications]]'''
+'''| [[Prasugrel contraindications|Contraindications]]'''
-'''| [[XXXXX warnings and precautions|Warnings and Precautions]]'''
+'''| [[Prasugrel warnings and precautions|Warnings and Precautions]]'''
-'''| [[XXXXX adverse reactions|Adverse Reactions]]'''
+'''| [[Prasugrel adverse reactions|Adverse Reactions]]'''
-'''| [[XXXXX drug interactions|Drug Interactions]]'''
+'''| [[Prasugrel drug interactions|Drug Interactions]]'''
-'''| [[XXXXX use in specific populations|Use in Specific Populations]]'''
+'''| [[Prasugrel use in specific populations|Use in Specific Populations]]'''
-'''| [[XXXXX overdosage|Overdosage]]'''
+'''| [[Prasugrel overdosage|Overdosage]]'''
-'''| [[XXXXX description|Description]]'''
+'''| [[Prasugrel description|Description]]'''
-'''| [[XXXXX clinical pharmacology|Clinical Pharmacology]]'''
+'''| [[Prasugrel clinical pharmacology|Clinical Pharmacology]]'''
-'''| [[XXXXX nonclinical toxicology|Nonclinical Toxicology]]'''
+'''| [[Prasugrel nonclinical toxicology|Nonclinical Toxicology]]'''
-'''| [[XXXXX clinical studies|Clinical Studies]]'''
+'''| [[Prasugrel clinical studies|Clinical Studies]]'''
-'''| [[XXXXX how supplied storage and handling|How Supplied/Storage and Handling]]'''
+'''| [[Prasugrel how supplied storage and handling|How Supplied/Storage and Handling]]'''
-'''| [[XXXXX patient counseling information|Patient Counseling Information]]'''
+'''| [[Prasugrel patient counseling information|Patient Counseling Information]]'''
-'''| [[XXXXX labels and packages|Labels and Packages]]'''
+'''| [[Prasugrel labels and packages|Labels and Packages]]'''
 ==Mechanism of Action==